12.20 USD
▼-0.48-3.79%
盘后 12.27 +0.55%
2026-09-15
市值
$1.06B
市盈率
—
EPS
-3.81
股息率
—
52 周区间
5.95 – 62.75
成交量
1.80M
Beta
1.03
目标价
28.54
52W 低 5.9552W 高 62.75
价格走势
公司简介
MoonLake Immunotherapeutics, a clinical-stage biotechnology company, focuses on developing therapies for inflammatory skin and joint diseases. It develops Sonelokimab, a novel tri-specific IL-17A and IL-17F inhibiting Nanobody for the treatment of inflammatory diseases in dermatology and rheumatology, as well as for hidradenitis suppurativa, psoriatic arthritis, axial spondyloarthritis, palmoplantar pustulosis, and psoriasis. The company was founded in 2021 and is headquartered in Zug, Switzerland.
关联新闻
- MoonLake's psoriatic arthritis drug meets key goals in late-stage trial
MoonLake Immunotherapeutics said on Monday its experimental drug met all main goals in a late-stage trial involving adults with an inflammatory disease who had not previously received biologic medic...